All In MedTech

Device Trial Radar · NCT06630546

Trabecular Microbypass IStent in Patients with Glaucoma

Last checked: Nov 20, 2026Latest source record: Oct 8, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

71

Actual

Start

May 16, 2022

Primary completion

Apr 30, 2023

Study completion Apr 30, 2023

Sponsor

Lead sponsor
Yu-Ting TsaoAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 8, 2024

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to assess the safety and efficacy of phacoemulsification combined with one trabecular micro-bypass stent implantation (phaco-iStent) versus phacoemulsification alone in a Taiwanese population, as well as to investigate any differences in outcomes between patients with primary open angle glaucoma (POAG) and those with normal tension glaucoma (NTG). The main question it aims to answer is: • How much do intraocular pressure (IOP) and the number of antiglaucoma medications change after iStent insertion, with subgroup analyses for POAG and NTG? Researchers will compare phacoemulsification combined with one trabecular micro-bypass stent implantation (phaco-iStent) versus phacoemulsification alone to see if IOP and the number of antiglaucoma medications decrease. Participants will receive their regular phacoemulsification and decided whether to receive iStent by themselves.

Conditions

  • Primary Open Angle Glaucoma (POAG)
  • Istent Inject W
  • Normal Tension Glaucoma (NTG)

Interventions

  • first generation iStent (Glaukos, San Clemente, CA, USA) insertionDevice

    In glaucoma patient who needed to receive cataract surgery, a standard phacoemulsification procedure was performed, along with the implantation of a foldable posterior chamber intraocular lens (PCIOL). Then, in adequate patient who wish to receive iStent insertion, we further inserted a preloaded micro-bypass stent (model GTS100L) through the temporal corneal incision into the nasal Schlemm's canal and checked the position. Adequate intraocular pressure (IOP) was assessed by palpation at the end of the surgery.

  • phacoemulsificationDevice

    A standard phacoemulsification procedure was performed, along with the implantation of a foldable posterior chamber intraocular lens (PCIOL).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Intraocular pressure (IOP) in mmHg or percentage changesTime frame: From enrollment to the end of treatment at 18 months
  2. glaucoma medication changes in numberTime frame: From enrollment to the end of treatment at 18 months
  3. Visual acuity changes in LogMAR scaleTime frame: From enrollment to the end of treatment at 18 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Chang Gung Memorial Hospital Linkou Branch

    Taoyuan City, No.5, Fuxing St., Guishan Dist.,, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.